A biopsy-based pilot clinical study: monitoring the effectiveness of tafamidis treatment of patients with transthyretin amyloid cardiomyopathy.

Back

ESC Professional Premium Access

A biopsy-based pilot clinical study: monitoring the effectiveness of tafamidis treatment of patients with transthyretin amyloid cardiomyopathy.

Session: Cardiac amyloidosis: prognosis and treatment monitoring

Topic: Infiltrative Myocardial Disease

Speaker: Doctor A. Elsanhoury (Berlin, DE)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Ahmed Elsanhoury

Charite University Hospital, Berlin (Germany)

2 presentations

1 follower

6 more presentations in this session

Prognostic value of different echocardiographic and cardiac magnetic resonance parameters in patients with AL amyloidosis

Speaker: Doctor A. Hernandez Martos (Salamanca, ES)

Echo-derived hemodynamic categorization for risk stratification in transthyretin cardiac amyloidosis

Speaker: Doctor A. Cantone (Ferrara, IT)

The electrophysiological substrate of biopsy-proven cardiac amyloidosis

Speaker: Associate Professor M. Casella (Ancona, IT)

Interleukin-6 plasma levels predict mortality and heart failure events in cardiac transthyretin amyloidosis

Speaker: Mr J. Lugitsch (Graz, AT)

Temporal trends and outcomes of heart failure patients between light-chain cardiac amyloidosis and transthyretin cardiac amyloidosis: insights from the national inpatient sample database

Speaker: Doctor K. Gandhi (New York, US)

Access the full session

Cardiac amyloidosis: prognosis and treatment monitoring

Speakers: Doctor A. Elsanhoury, Doctor A. Hernandez Martos, Doctor A. Cantone, Associate Professor M. Casella, Mr J. Lugitsch...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources